(CercleFinance.com) – Biocorp shares gained more than 3% on Tuesday on the Paris Stock Exchange following the announcement of a partnership in Japan around Mallya, its connected device for insulin pens.
The Health2Sync health platform announced this morning the signing of a partnership with the French and Danish company Novo Nordisk to integrate Mallya technology.
Under the terms of the agreement, the 350,000 Japanese patients using the Health2Sync app will be able to automatically sync their recorded data from the Mallya sensor.
This device, designed by Biocorp and marketed in Japan by Novo Nordisk, is intended for insulin injector pens in order to monitor the doses injected and promote better compliance with treatment for people with diabetes.
‘This partnership is the first global integration of its kind and will allow patients on insulin to take care of their health by entering several types of data, starting with the monitoring of their insulin injections’, is it underlined in the Health2Sync press release.
The population of people with diabetes and prediabetes is currently believed to exceed 20 million in Japan, with a high rate of 44% missing or misadministering prescribed insulin doses.
Created in 2013 in Asia, Health2Sync is a platform for people suffering from chronic diseases allowing them to benefit from personalized care advice.
Around 3:50 p.m., the title Biocorp advanced by 3.6% while the CAC Mid & Small index of the Paris Bourse fell by 0.4% at the same time.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about BIOCORP in real time: